首页 | 本学科首页   官方微博 | 高级检索  
检索        


Rituximab,cladribine, and cyclophosphamide (RCC) induction with rituximab maintenance in chronic lymphocytic leukemia: PALG ‐ CLL4 (ML21283) trial
Authors:Tadeusz Robak  Jerzy Błoński  Aleksander Bartłomiej Skotnicki  Magdalena Piotrowska  Tomasz Wróbel  Justyna Rybka  Janusz Kłoczko  Łukasz Bołkun  Bożena Katarzyna Budziszewska  Urszula Walczak  Anatoly Uss  Marta Fidecka  Piotr Smolewski
Institution:1. Department of Hematology, Copernicus Memorial Hospital, Medical University of Lodz, Lodz, Poland;2. Department of Hematology, Jagiellonian University, Kraków, Poland;3. Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland;4. Department of Hematology, Medical University of Bia?ystok, Bia?ystok, Poland;5. Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland;6. City Clinical Hospital No. 9, Minsk, Belarus;7. Roche Poland, Warsaw, Poland;8. Department of Experimental Hematology, Copernicus Memorial Hospital, Medical University of Lodz, Lodz, Poland
Abstract:
Keywords:chronic lymphocytic leukemia  first line  maintenance  RCC regimen  rituximab
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号